Bellicum Pharmaceuticals Inc (BLCM) Expected to Announce Quarterly Sales of $80,000.00
Wall Street brokerages predict that Bellicum Pharmaceuticals Inc (NASDAQ:BLCM) will report sales of $80,000.00 for the current quarter, Zacks Investment Research reports. Three analysts have issued estimates for Bellicum Pharmaceuticals’ earnings. The highest sales estimate is $100,000.00 and the lowest is $30,000.00. Bellicum Pharmaceuticals posted sales of $130,000.00 during the same quarter last year, which would indicate a negative year over year growth rate of 38.5%. The company is scheduled to report its next earnings results on Tuesday, November 6th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full-year sales of $620,000.00 for the current fiscal year, with estimates ranging from $400,000.00 to $1.00 million. For the next financial year, analysts anticipate that the firm will post sales of $3.90 million per share, with estimates ranging from $300,000.00 to $11.00 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that that provide coverage for Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last posted its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.05). The company had revenue of $0.36 million for the quarter, compared to analysts’ expectations of $0.08 million.
In other Bellicum Pharmaceuticals news, insider David M. Spencer sold 40,000 shares of Bellicum Pharmaceuticals stock in a transaction dated Wednesday, July 18th. The shares were sold at an average price of $7.63, for a total transaction of $305,200.00. Following the transaction, the insider now directly owns 99,939 shares of the company’s stock, valued at $762,534.57. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 9.84% of the company’s stock.
A number of hedge funds have recently modified their holdings of BLCM. Frazier Management LLC purchased a new position in Bellicum Pharmaceuticals during the second quarter worth about $7,760,000. BlackRock Inc. raised its stake in Bellicum Pharmaceuticals by 37.5% during the second quarter. BlackRock Inc. now owns 3,112,394 shares of the biopharmaceutical company’s stock worth $22,970,000 after purchasing an additional 849,208 shares during the period. Wasatch Advisors Inc. raised its stake in Bellicum Pharmaceuticals by 1,004.4% during the second quarter. Wasatch Advisors Inc. now owns 923,824 shares of the biopharmaceutical company’s stock worth $6,818,000 after purchasing an additional 840,175 shares during the period. JPMorgan Chase & Co. raised its stake in Bellicum Pharmaceuticals by 22.4% during the first quarter. JPMorgan Chase & Co. now owns 2,863,044 shares of the biopharmaceutical company’s stock worth $18,782,000 after purchasing an additional 523,976 shares during the period. Finally, Millennium Management LLC raised its stake in Bellicum Pharmaceuticals by 198.5% during the second quarter. Millennium Management LLC now owns 733,850 shares of the biopharmaceutical company’s stock worth $5,416,000 after purchasing an additional 487,982 shares during the period. 59.31% of the stock is currently owned by institutional investors.
BLCM opened at $7.05 on Friday. The stock has a market cap of $306.91 million, a P/E ratio of -2.48 and a beta of 0.45. Bellicum Pharmaceuticals has a twelve month low of $5.02 and a twelve month high of $13.30. The company has a current ratio of 10.24, a quick ratio of 10.24 and a debt-to-equity ratio of 0.32.
Bellicum Pharmaceuticals Company Profile
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.